Literature DB >> 6806311

Familial euthyroid thyroxine excess: characterization of abnormal intermediate affinity thyroxine binding to albumin.

J W Barlow, J M Csicsmann, E L White, J W Funder, J R Stockigt.   

Abstract

The abnormal high capacity T4 binding site of familial euthyroid T4 excess was separable from prealbumin and T4-binding globulin but not from albumin. We therefore compared T4 binding by albumin preparations isolated from the sera of normal and affected subjects. By equilibrium dialysis, albumin from affected subjects showed an extra T4 binding site (Kd approximately 50 nM) in addition to the T4 binding sites of normal albumin (Kd approximately 4 microM). Comparison of the estimated capacity of the additional site (200 microM) with the molar concentration of albumin suggested that only about one third of albumin molecules from affected subjects contained the extra binding site. Estimates of affinity and capacity were used to derive combining powers for the diverse classes of serum T4 binding sites. From these estimates, it appears that the presence of the abnormal site accounts for the approximate doubling of normal mean total T4 (from approximately 100 nM or 7.7 micrograms/dl to approximately 200 nM or 15.5 micrograms/dl), in order to maintain a normal free T4 in the face of the increased T4 association with albumin. Studies of [125I]T4 displacement from albumin of affected subjects showed low T3 affinity and competition by barbitone. Relative molar concentrations to give equivalent displacement of [125I]T4 were: 3,3',5,5'-tetraiodothyroacetic acid, 0.4; T4, 1.0; rT3, 4; 8-anilinonaphthalene sulfonic acid, 10; T3, 80; salicylate, 200; and barbitone, 40,000. Studies with dithiothreitol suggested that disulfide bonds were critical in maintaining the T4-albumin association. These findings indicate that familial T4 excess is due to abnormal intermediate affinity, sulfhydryl-sensitive T4 binding sites that are inseparable from the albumin found in affected subjects.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6806311     DOI: 10.1210/jcem-55-2-244

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

Review 1.  Euthyroid hyperthyroxinemia.

Authors:  R Rajatanavin; L E Braverman
Journal:  J Endocrinol Invest       Date:  1983-12       Impact factor: 4.256

2.  A four generation study of familial dysalbuminemic hyperthyroxinemia: diagnosis in the presence of an acquired excess of thyroxine-binding globulin.

Authors:  P P Yeo; Y Yabu; J R Etzkorn; R Rajatanavin; L E Braverman; S H Ingbar
Journal:  J Endocrinol Invest       Date:  1987-02       Impact factor: 4.256

3.  Thyroxine uptake by perfused rat liver. No evidence for facilitation by five different thyroxine-binding proteins.

Authors:  C M Mendel; R A Weisiger
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

4.  A new type of albumin with predominantly increased binding affinity for 3,3',5-triiodothyronine in a patient with Graves' disease.

Authors:  Y Yabu; K Miyai; A Kobayashi; K Miki; K Doi; J Takamatsu; T Mozai; F Matsuzuka; K Kuma
Journal:  J Endocrinol Invest       Date:  1987-04       Impact factor: 4.256

5.  Detection of familial dysalbuminaemic hyperthyroxinaemia.

Authors:  M S Croxson; B N Palmer; I M Holdaway; P A Frengley; M C Evans
Journal:  Br Med J (Clin Res Ed)       Date:  1985-04-13

6.  A point mutation in the human serum albumin gene results in familial dysalbuminaemic hyperthyroxinaemia.

Authors:  C E Petersen; A G Scottolini; L R Cody; M Mandel; N Reimer; N V Bhagavan
Journal:  J Med Genet       Date:  1994-05       Impact factor: 6.318

Review 7.  Familial dysalbuminaemic hyperthyroxinaemia: a review.

Authors:  I W Jensen; J Faber
Journal:  J R Soc Med       Date:  1988-01       Impact factor: 18.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.